A new COVID-19 vaccine produces antibodies specific to SARS-CoV-2 at quantities believed sufficient for neutralizing the virus, a mouse model study reveals. The new vaccine using an innovative microneedle array on fingertip-sized pads, which increases the vaccine potency.